| This report contains COVID-19 specific updates.
2021 Pharmaceuticals Research Review
Report Highlights
- The global market for generic drugs should grow from $411.6 billion in 2020 to $650.3 billion by 2025, at compound annual growth rate (CAGR) of 9.6% for the period of 2020-2025.
- The global market for orphan drugs should grow from $190.8 billion in 2021 to $248.2 billion by 2026, at compound annual growth rate (CAGR) of 5.4% for the period of 2021-2026.
- The global market for oncology pharmaceuticals should grow from $177.4 billion in 2021 to $313.7 billion by 2026, at compound annual growth rate (CAGR) of 12.1% for the period of 2021-2026.
The world pharmaceutical market was worth an estimated $1.2 trillion at ex-factory prices in 2020. It is one of the top performing industries globally. New medications are constantly being developed, approved and marketed, resulting in significant market growth. The FDA approved 55 novel drugs in 2021. Other market growth drivers include the aging population, as seniors use more medicines per capita and there is a rise in the prevalence and treatment of chronic diseases. Immunology, oncology and neurology are the fastest-growing therapy areas and are expected to be the main sources of growth through 2026. The biologics market is growing at significant rate and is expected to continue outstripping that of small molecules in coming decade. The three largest biologic therapy areas include oncology, autoimmune and diabetes.
The U.S. dominates the global pharmaceutical markets, accounting for almost half of pharmaceutical sales globally in 2021. However, the industry faces many challenges including regulatory hurdles, escalating R&D costs, and competition from generic drugs and biosimilars. The pharmaceutical industry, one of the most profitable industries in the world, is under significant pressure to bring in cost-effective and innovative drugs. The discipline of precision medicine and genomic medicine has gained significant interest from researchers and healthcare providers globally. Already, it is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease, and its popularity is expected to grow significantly in coming years. Sensing the huge opportunity in the field of precision medicine and genomic medicine, several big pharma companies have been making huge investments to expand their precision and genomic medicine portfolios and pipelines. The number of personalized drugs is expected to double or even triple in the upcoming years.
This Pharmaceutical Research Review provides a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision making since the inception of BCC Research in 1971. It includes the highlights of reports published in late 2020 and 2021 on the following markets:
- PHM009J Global Markets for Generic Drugs
- PHM038F Global Markets for Orphan Drugs
- PHM256A Global Oncology Pharmaceutical Market
- PHM249A Immunotherapy Drugs: Global Markets
- PHM061E Global Markets for Infectious Disease Treatments
- PHM237A Pharmaceutical Treatments for Mental Health Disorders: Global Markets
- PHM010L Excipients in Pharmaceuticals: Global Markets to 2026
- PHM244A Softgel Capsules: Global Markets
- PHM043H Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging
- PHM248A Pharma 4.0 Market
- PHM149B Neurostimulation: Technologies and Global Markets
We hope you find this Research Review valuable, and we look forward to serving our customers’ pharmaceutical market research needs.
Analyst's Credentials
BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials, and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.
Report Highlights
- The global checkpoint inhibitors market should reach $29.3 billion by 2023 from $14.9 billion in 2018 at a compound annual growth rate (CAGR) of 14.4% for the period 2018 to 2023.
- The global lysosomal storage diseases market should reach $7.6 billion by 2023 from $5.1 billion in 2018 at a compound annual growth rate (CAGR) of 8.3% for the period 2018 to 2023.
- The global high-throughput screening market should reach $21 billion by 2023 from $14.4 billion in 2018 at a compound annual growth rate (CAGR) of 7.9% for the period 2018 to 2023.
Report Highlights
- The global market for cancer vaccines totaled $4.5 billion in 2013 and reached nearly $4.0 billion in 2014. This market is expected to reach $4.3 billion by 2019, registering a compound annual growth rate (CAGR) of 1.3% for the period 2014-2019.
- The global market for “silent” cancers was valued at $8.5 billion in 2013 and $9 billion in 2014. This market is expected to reach almost $13.6 billion by 2019, with a CAGR of 8.5% from 2014 to 2019.
- The global market for incretin-based therapeutics was valued at nearly $11.8 billion in 2013 and $12.7 billion in 2014. This market is expected to reach $22.8 billion by 2019, with a CAGR of 12.4% from 2014 to 2019.
Report Highlights
- The global anticoagulant drug market was valued at nearly $5.8 billion in 2011 and should reach nearly $5.7 billion in 2012. Total market value is expected to reach nearly $5.4 billion in 2017 after decreasing at a five-year compound annual growth rate (CAGR) of -1.1%.
- The market for global drug device combination products was valued at $18.5 billion in 2011 and should reach $19 billion in 2012. Total market value is expected to reach $30.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.9%.
- The global market for treatment and diagnosis of sexually transmitted diseases was valued at $28.2 billion in 2011 and $33.2 billion in 2012. Total market value is expected to reach nearly $52 billion in 2017 after increasing at a five-year compound annual growth rate of 9.3%.
Report Highlights
This review of pharmaceutical market research provides:
- Analysis and the future direction of treatments for neurodegenerative (i.e., progressive ataxia and weakness) disorders as the market efforts toward drug and therapy development evolve.
- Coverage of approved human antifungal therapeutics with a heavy focus on therapeutics in early development.
- Profiles of manufacturers of leading asthma and chronic obstructive pulmonary disease (COPD) prescription drugs.
- Comprehensive analysis of the market for genitourinary drugs on a global basis.
- Current and future characteristics of the global markets for treatments for syndromes of dementia and movement disorders.
Report Highlights
- The global market for marine-derived drugs by type was around $4.8 billion in 2011, which is expected to be around $5.3 billion in 2012. This global market is forecasted to reach $8.6 billion by 2016 at a compound annual growth rate (CAGR) of 12.5% for the five year period of 2011 to 2016.
- The overall emerging markets for therapeutic drugs totaled $131.4 billion in 2009. These regions include Latin America, China, Eastern Europe, the Middle East, South Korea, India, Russia, and South Africa. These regions are estimated at $145.8 billion in 2010 and expected to continue aggressive growth through 2015, reaching a figure of $214.2 billion, yielding a compound annual growth rate (CAGR) of 8% from 2010 to 2015.
- The global market for blood-brain barrier (BBB) technology for therapeutics amounted to $12.3 million in 2010 and will reach $387 million by 2015, a compound annual growth rate (CAGR) of 99.3%.
Report Highlights
-
The global ophthalmic market grew to $15.5 billion in 2009, showing resistance to the global recession. The sector will continue to grow through 2014 to $20.6 billion, a compound annual growth rate (CAGR) of 5.9%.
-
Total sales of drug-device combination products worldwide were valued at $12 billion in 2008. The overall market is increasing at a compound annual growth rate (CAGR) of 14.5% per year and thus sales are projected to reach $27 billion by 2014. Overall, sales in the U.S. represent about a third of total industry revenues.
-
The global cardiovascular market was valued at $140.7 billion in 2009, and is expected to continue to grow in 2010 to $144.5 billion by a compound annual growth rate (CAGR) of 2.7%. The sector will experience a sizable reduction in the early portion of the forecast period, and then slowly rise to a net small reduction by 2015 on a CAGR basis of -0.7%, to a figure of $139.8 billion.